Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Payables (2020 - 2025)

Historic Payables for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to $25.8 million.

  • HCW Biologics' Payables fell 1113.89% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.8 million, marking a year-over-year decrease of 1113.89%. This contributed to the annual value of $28.6 million for FY2024, which is 36450.31% up from last year.
  • According to the latest figures from Q3 2025, HCW Biologics' Payables is $25.8 million, which was down 1113.89% from $25.8 million recorded in Q2 2025.
  • HCW Biologics' 5-year Payables high stood at $29.0 million for Q3 2024, and its period low was $743120.0 during Q1 2022.
  • For the 5-year period, HCW Biologics' Payables averaged around $10.5 million, with its median value being $3.3 million (2021).
  • Per our database at Business Quant, HCW Biologics' Payables tumbled by 7326.0% in 2022 and then skyrocketed by 81972.56% in 2024.
  • HCW Biologics' Payables (Quarter) stood at $2.1 million in 2021, then dropped by 17.6% to $1.7 million in 2022, then skyrocketed by 256.42% to $6.2 million in 2023, then surged by 364.5% to $28.6 million in 2024, then dropped by 10.02% to $25.8 million in 2025.
  • Its Payables stands at $25.8 million for Q3 2025, versus $25.8 million for Q2 2025 and $26.0 million for Q1 2025.